高龄射血分数降低心衰患者使用RAS抑制剂与死亡/发病的关联:前瞻性倾向评分匹配队列研究
该研究基于瑞典心衰注册数据,纳入年龄>80岁且射血分数<40%的HFrEF患者,通过倾向评分1:1匹配比较使用与未使用RAS抑制剂者的全因死亡及全因死亡/心衰住院风险。结果显示RAS抑制剂使用与全因死亡风险降低(HR 0.78,95%CI 0.72-0.86)及全因死亡/心衰住院风险降低(HR 0.86,95%CI 0.79-0.94)相关,且≤80岁阳性对照队列结果一致。
要点
- 年龄>80岁HFrEF患者中RAS抑制剂使用率80%,相对低于较年轻患者。
- RAS抑制剂与全因死亡风险降低相关(HR 0.78,95%CI 0.72-0.86)。
- RAS抑制剂与全因死亡/心衰住院风险降低相关(HR 0.86,95%CI 0.79-0.94)。
核心结论
- 在年龄>80岁HFrEF患者中,RAS抑制剂使用与全因死亡及全因死亡/心衰住院风险降低相关,且与≤80岁患者中的关联相似。
- RAS抑制剂在该高龄HFrEF亚组中相对使用不足,尽管关联结果与较年轻患者类似且未观察到与晕厥相关住院风险的明显关联。
研究设计与样本
- 前瞻性倾向评分匹配队列研究,数据来自瑞典心力衰竭注册。
- 纳入射血分数<40%且年龄>80岁的HFrEF患者,共6710例,中位年龄85(82-87)岁,女性占38%。
- 基于37个变量计算RAS抑制剂使用的倾向评分,进行1:1匹配,匹配后队列2416例,年龄86(83-91)岁。
- 采用Cox回归模型比较RAS抑制剂使用与否的全因死亡及全因死亡/心衰住院结局,并在年龄≤80岁阳性对照队列中重复分析。
主要发现
- 6710例患者中5384例(80%)接受RAS抑制剂治疗。
- 匹配后队列中,RAS抑制剂使用与全因死亡风险降低相关,HR 0.78(95%CI 0.72-0.86)。
- RAS抑制剂使用与全因死亡/心衰住院风险降低相关,HR 0.86(95%CI 0.79-0.94)。
临床怎么用
- 对于年龄>80岁的HFrEF患者,RAS抑制剂使用与较年轻患者相似的死亡/发病风险降低相关,支持在这一高龄亚组中考虑使用RAS抑制剂。
- 研究结果提示可将高龄作为RAS抑制剂治疗的考虑因素之一,但仍需随机临床试验验证。
局限性
- 研究为观察性设计,尽管采用倾向评分匹配,仍可能存在未测量混杂。
- 作者指出结果应视为 hypothesis generating,需随机临床试验验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
AIMS: In heart failure with reduced ejection fraction (HFrEF), renin-angiotensin system inhibitors (RASi) improve morbidity and mortality. However, patients aged >80 years constituted a small minority in trials. We assessed the association between RASi use and mortality/morbidity in HFrEF patients aged >80 years. METHODS AND RESULTS: We included patients with ejection fraction <40% and age >80 years from the Swedish Heart Failure Registry. Propensity scores for RASi use were calculated from 37 variables. Cox regression models for RASi vs. non-RASi with all-cause mortality and all-cause mortality/heart failure (HF) hospitalization as outcomes were fitted in a 1:1 propensity-score-matched cohort. To assess consistency, the same analyses were performed in a 'positive control' cohort aged ≤80 years. Of 6710 patients [median age (interquartile range) 85 (82-87) years; 38% women], 5384 (80%) received RASi. Propensity-score matching yielded 2416 patients, [age 86 (83-91) years]. RASi use was associated with hazard ratio (HR) (95% confidence interval) 0.78 (0.72-0.86) for all-cause mortality and 0.86 (0.79-0.94) for all-cause mortality/HF hospitalization. In positive control patients aged ≤80 years (17 842 patients in the overall cohort, 2126 after matching), HR for all-cause mortality was 0.81 (0.71-0.91), whereas it was 0.85 (0.76-0.94) for all-cause mortality/HF hospitalization. CONCLUSION: In HFrEF patients with age >80 years, RASi were relatively underused compared with in younger patients, despite similar association with reduced morbidity and mortality and no apparent association with risk of syncope-related hospitalization. These results may be interpreted as hypothesis generating for randomized clinical trials on RASi in this elderly HFrEF subpopulation.
引用
- Savarese G, Dahlström U, Vasko P, et al. Association between renin-angiotensin system inhibitor use and mortality/morbidity in elderly patients with heart failure with reduced ejection fraction: a prospective propensity score-matched cohort study. Eur Heart J. 2018. PMID: 30351407. doi:10.1093/eurheartj/ehy621
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。